Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Allison Lapins

Behavioral Neurology & Neuropsychiatry Chicago, IL Medical Doctor

NPI 1467983965 CMS profile 3566193

676 N Saint Clair St Ste 945, Chicago, IL 60611

Open in the dashboard

General payments

$1,382

2 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Lapins of Chicago, IL is reported in the CMS Open Payments database as having received $1,382 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Behavioral Neurology & Neuropsychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,313 1
2024 General $69 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Lapins
  • Behavioral Neurology & Neuropsychiatry median
  • Middle half of Behavioral Neurology & Neuropsychiatry
  • National median

In program year 2025, general payments to Allison Lapins were reported at $1,313. Among 74 Behavioral Neurology & Neuropsychiatry profiles paid that year, the median was $152 and the middle half received between $53 and $1,035.

Show as a table
Year Allison Lapins Behavioral Neurology & Neuropsychiatry median Middle half National median
2019 $0 $211 $86–$990 $163
2020 $0 $270 $54–$1,600 $114
2021 $0 $267 $60–$1,036 $132
2022 $0 $255 $69–$1,314 $149
2023 $0 $170 $50–$1,103 $160
2024 $69 $173 $39–$1,488 $164
2025 $1,313 $152 $53–$1,035 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Lilly USA, LLC $1,313 1 payment
  2. Eli Lilly and Company $69 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Consulting Fee $1,313 1 payment
  2. Food and Beverage $69 1 payment
Products named General payments · program years 2024–2025
  1. KISUNLA $1,382 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

931

Median for Neurology: 833

Drug cost

$32,932

Median for Neurology: $202,670

Branded share of claims

13.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rivastigmine Generic 37 $8,081
Memantine Hcl Er Memantine Hcl Brand 43 $6,801
Memantine Hcl Generic 128 $5,930
Donepezil Hcl Generic 263 $3,677
Mirtazapine Generic 19 $1,374
Quetiapine Fumarate Generic 84 $1,202
Galantamine Hbr Generic 42 $1,074
Sertraline Hcl Generic 95 $848
Divalproex Sodium Generic 11 $725
Rivastigmine Rivastigmine Tartrate Brand 20 $642

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$40,048

Medicare's payments for the services billed

Medicare patients

153

Average age 77

Services billed

451

98 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 73%
High blood pressure 58%
Arthritis 39%
Depression 29%
Osteoporosis 25%
Ischemic heart disease 22%
Cancer 22%
Diabetes 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISUNLA
  • Eli Lilly and Company $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Behavioral Neurology & Neuropsychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record